@article{6638920bec6c40bba49245ac2935cd49,
title = "Response rate profiles for major depressive disorder: Characterizing early response and longitudinal nonresponse",
abstract = "Background: Definition of response is critical when seeking to establish valid predictors of treatment success. However, response at the end of study or endpoint only provides one view of the overall clinical picture that is relevant in testing for predictors. The current study employed a classification technique designed to group subjects based on their rate of change over time, while simultaneously addressing the issue of controlling for baseline severity. Methods: A set of latent class trajectory analyses, incorporating baseline level of symptoms, were performed on a sample of 344 depressed patients from a clinical trial evaluating the efficacy of cognitive behavior therapy and two antidepressant medications (escitalopram and duloxetine) in patients with major depressive disorder. Results: Although very few demographic and illness-related features were associated with response rate profiles, the aggregated effect of candidate genetic variants previously identified in large pharmacogenetic studies and meta-analyses showed a significant association with early remission as well as nonresponse. These same genetic scores showed a less compelling relationship with endpoint response categories. In addition, consistent nonresponse throughout the study treatment period was shown to occur in different subjects than endpoint nonresponse, which was verified by follow-up augmentation treatment outcomes. Conclusions: When defining groups based on the rate of change, controlling for baseline depression severity may help to identify the clinically relevant distinctions of early response on one end and consistent nonresponse on the other.",
keywords = "CBT/cognitive behavior therapy, antidepressants, depression, genetics, treatment",
author = "Kelley, {Mary E.} and Dunlop, {Boadie W.} and Nemeroff, {Charles B.} and Adriana Lori and Tania Carrillo-Roa and Binder, {Elisabeth B.} and Kutner, {Michael H.} and Rivera, {Vivianne Aponte} and Craighead, {W. Edward} and Mayberg, {Helen S.}",
note = "Funding Information: Dr. Nemeroff reports grants from NIH, personal fees from Xhale, Takeda, Prismic, Taisho Pharmaceutical Inc., Janssen, Magstim, Bracket/Clintara, Total Pain Solutions, Gerson Lehrman Group, Fortress Biotech, Sunovion, Sumitomo Dainippon, Celgene, Seattle Genetics, Abbvie, OPKO Health, and Network Life Sciences, other from AFSP, BBRF, ADAA, Skyland Trail, RiverMend, LIBR, Gratitude America, Method and devices for transdermal delivery of lithium (US 6,375,990B1), Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2), personal fees from Navitor Pharmaceuticals, TC MSO, ITI Inc., Antares, BI Gen Holdings, grants from Stanley Medical Research Institute, personal fees from Corcept Therapeutics Pharmaceuticals Company, outside the submitted work. Funding Information: Dr. Dunlop reports grants from Assurex Health, Acadia, Axsome, Janssen, Otsuka, Forest, and Takeda, outside the submitted work. Funding Information: We thank Flavia Mercado for her assistance in operationalizing the study at the Grady Hospital location. Dr. Mayberg reports grants from NIMH, non-financial support from Eli LIlly, non-financial support from Forrest Labs, during the conduct of the study; other from St Jude Medical, Inc, outside the submitted work; In addition, Dr. Mayberg has a patent Method for Treating Depression Mood Disorders and Anxiety Disorders using Neuromodulation licensed to St. Jude Medical Inc. Dr. Dunlop reports grants from Assurex Health, Acadia, Axsome, Janssen, Otsuka, Forest, and Takeda, outside the submitted work. Dr. Craighead reports grants from NIMH, during the conduct of the study; other from Mary & John Brock, Fuqua Family Foundation, Hugarheill eff, John Wiley & Sons, personal fees from George West Mental Health Foundation, Scientific Advisory Board, AIM for Mental Health, outside the submitted work. Dr. Nemeroff reports grants from NIH, personal fees from Xhale, Takeda, Prismic, Taisho Pharmaceutical Inc., Janssen, Magstim, Bracket/Clintara, Total Pain Solutions, Gerson Lehrman Group, Fortress Biotech, Sunovion, Sumitomo Dainippon, Celgene, Seattle Genetics, Abbvie, OPKO Health, and Network Life Sciences, other from AFSP, BBRF, ADAA, Skyland Trail, RiverMend, LIBR, Gratitude America, Method and devices for transdermal delivery of lithium (US 6,375,990B1), Method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2), personal fees from Navitor Pharmaceuticals, TC MSO, ITI Inc., Antares, BI Gen Holdings, grants from Stanley Medical Research Institute, personal fees from Corcept Therapeutics Pharmaceuticals Company, outside the submitted work. Publisher Copyright: {\textcopyright} 2018 Wiley Periodicals, Inc.",
year = "2018",
month = oct,
doi = "10.1002/da.22832",
language = "English (US)",
volume = "35",
pages = "992--1000",
journal = "Anxiety",
issn = "1091-4269",
publisher = "Wiley-Blackwell",
number = "10",
}